Vijay Kumar

Intuitive Surgical, Inc. (NASDAQ: ISRG) is scheduled to report its second quarter results after Tuesday's market close. Estimize is expecting the company to earn $4.05 per share (based on 38 estimates) on revenue of $570.82 million. This compares to the Wall Street consensus estimate...

Becton, Dickinson and Co.'s (NYSE: BDX) planned $12 billion acquisition of CareFusion Corporation (NYSE: CFN) may have far-flung effects on the medical technology sector, an analyst said Tuesday. Stifel's Richard Wise said the deal may force C.R. Bard Inc. to "bulk up" with a...

Intuitive Surgical (NASDAQ: ISRG) introduced its Da Vinci Xi Surgical system on Tuesday. The company is stating that its new machine, which has already been approved by the FDA, has broader capabilities than prior generations. The new surgical system allows the surgeon to have a greater range of...

ISI analyst Vijay Kumar reported Qiagen N. V. (NASDAQ: QGEN) may have repercussions from reimbursements from coding changes issues. Qiagen short interest rose to a 2-Year high before the third quarter. Kumar noted that Quest Diagnostics Inc. (NYSE: DGX) preliminary earnings are taking a hit due...

In a report published Friday, ISI Group analyst Vijay Kumar downgraded the rating on Cepheid (NASDAQ: CPHD) from Cautious to Sell, but raised the price target from $32.50 to $34.00. In the report, ISI Group noted, “We are downgrading CPHD shares to Sell as we see >10% downside from current...

In a report published Tuesday, ISI Group analyst Vijay Kumar upgraded the rating on Hologic (NASDAQ: HOLX) from Buy to Strong Buy, and raised the price target from $25.00 to $25.50. In the report, ISI Group noted, “Hologic's strategic decision to diversify its revenue base via acquisitions hasn't...

In a report published Tuesday, ISI Group analyst Vijay Kumar initiated coverage on Becton, Dickinson and Co. (NYSE: BDX) with a Buy rating and $106.50 price target. In the report, ISI Group noted, “We view Becton, Dickinson and Co (BDX) as a premier provider of medical devices, diagnostic...

Deutsche Bank analysts Ross Muken, Michael Cherny, and Vijay Kumar reiterated a Buy rating and %78 price target for Medco (NYSE: MHS). The analysts see sustained growth at Medco, driven by several drivers, including growth in generics, mail, and PGx. They said, "While there is some debate on the...

Deutsche Bank Securities analysts Ross Muken, Michael Cherny and Vijay Kumar reiterated their Buy rating for shares of MedcoHealth Solutions Inc (NYSE: MHS), with a price target of $78 per share. The analysts reiterated their Buy rating for MedcoHealth Solutions Inc after the company's board of...